T1	HMM 228 246	antitumor activity
T2	HMM 251 257	safety
T3	HMM 813 838	Grades 3 and 4 toxicities
T4	HMM 888 899	neutropenia
T5	HMM 907 914	fatigue
T6	HMM 925 935	neuropathy
T7	HMM 949 981	ixabepilone arm, and neutropenia
T8	HMM 989 1008	febrile neutropenia
T9	HMM 1015 1022	fatigue
T10	HMM 1029 1039	neuropathy
T11	HMM 1050 1060	thrombosis
T12	HMM 1123 1148	prostate-specific antigen
T13	HMM 1363 1380	partial responses
T14	HMM 1538 1583	Time to prostate-specific antigen progression
T15	HMM 1790 1804	well tolerated
T16	HMM 1813 1831	antitumor activity
